TRACON Pharmaceuticals (TCON)
(Delayed Data from OTC)
$0.18 USD
-0.03 (-15.66%)
Updated Sep 20, 2024 03:30 PM ET
NA Value
NA Growth NA Momentum NA VGMIncome Statements
Fiscal Year end for TRACON Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 12 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 12 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 21 | 28 | 29 | 16 | 22 |
Income After Depreciation & Amortization | -9 | -28 | -28 | -16 | -22 |
Non-Operating Income | 13 | 0 | 0 | 0 | 0 |
Interest Expense | 7 | 1 | 0 | 1 | 0 |
Pretax Income | -4 | -29 | -29 | -17 | -23 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -4 | -29 | -29 | -17 | -23 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -4 | -29 | -29 | -17 | -23 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -2 | -27 | -28 | -16 | -22 |
Depreciation & Amortization (Cash Flow) | 7 | 1 | 0 | 0 | 0 |
Income After Depreciation & Amortization | -9 | -28 | -28 | -16 | -22 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 1.64 | 1.05 | 0.86 | 0.45 | 0.15 |
Diluted EPS Before Non-Recurring Items | -2.20 | -27.80 | -33.20 | -37.40 | -149.40 |
Diluted Net EPS (GAAP) | -2.20 | -27.80 | -33.20 | -37.40 | -149.40 |
Fiscal Year end for TRACON Pharmaceuticals, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | 0.06 | 0.10 | 3.05 | 0.00 | 9.00 |
Cost Of Goods | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | 0.06 | 0.10 | 3.05 | 0.00 | 9.00 |
SG&A, R&D, and Dept/Amort Expenses | 2.97 | 3.31 | 2.63 | 1.59 | 9.78 |
Income After SG&A, R&D, and Dept/Amort Expenses | -2.91 | -3.21 | 0.42 | -1.59 | -0.78 |
Non-Operating Income | 0.00 | -0.01 | 0.00 | 13.00 | 0.00 |
Interest Expense | -0.08 | -0.05 | -0.04 | 0.65 | 5.51 |
Pretax Income | -2.84 | -3.17 | 0.44 | 10.76 | -6.29 |
Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | -2.84 | -3.17 | 0.44 | 10.76 | -6.29 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | -2.84 | -3.17 | 0.44 | 10.76 | -6.29 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | 3.01 | 2.39 | 2.01 | 1.84 | 1.54 |
Diluted EPS Before Non-Recurring Items | -0.94 | -1.33 | 0.20 | 5.80 | -1.20 |
Diluted Net EPS (GAAP) | -0.94 | -1.33 | 3.20 | 5.80 | -4.00 |